arginase inhibitor in the pharmacological correction of endothelial dysfunction
;Mihail V. Pokrovskiy;Mihail V. Korokin;Svetlana A. Tsepeleva;Tatyana G. Pokrovskaya;Vladimir V. Gureev;Elena A. Konovalova;Oleg S. Gudyrev;Vladimir I. Kochkarov;Liliya V. Korokina;Eleonora N. Dudina;Anna V. Babko;Elena G. Terehova
molecular biology and evolution2011Vol. 2011pp. -
103
pokrovskiy2011internationalarginase
Abstract
This paper is
about a way of correction of endothelial
dysfunction with the inhibitor of
arginase: L-norvaline. There is an
imbalance between vasoconstriction and
vasodilatation factors of endothelium on the basis
of endothelial dysfunction. Among vasodilatation
agents, nitrogen oxide plays the basic role.
Amino acid L-arginine serves as a source of molecules of nitrogen oxide in an
organism. Because of the high activity of arginase enzyme which
catalyzes the hydrolysis of L-arginine into
ornithine and urea, the bioavailability of
nitrogen oxide decreases. The inhibitors of
arginase suppress the activity of the given enzyme,
raising and production of nitrogen oxide, preventing
the development of endothelial
dysfunction.